Nanose Medical

Company Overview

Snapshot

Founded in October 2019 by Orit Marom Albeck, Ilay Marom, Osnat Sella Tavor, and Prof. Hossam Haick, Nanose Medical operates with 1–10 employees. The company has raised a total of $10.58 million across 7 funding rounds and has received grants from the European Innovation Council and Horizon Europe. In May 2024, the European Innovation Council provided a grant of $3 million to Nanose Medical.

Business overview

Nanose Medical is a Health Tech & Life Sciences company developing non-invasive, AI-driven breath-sensing devices for early disease detection. Its core technology identifies unique biomarker fingerprints in breath, currently applied to screening for lung cancer and advanced liver fibrosis (MASH). The company's solutions aim to provide affordable, accurate point-of-care screening, addressing critical gaps in risk stratification and improving patient outcomes in the healthcare sector, particularly for providers.

Strategic signal

In June 2025, Nanose Medical was highlighted for its pioneering work in non-invasive, breath-based diagnostics, backed by Google and the EU. This signals strong strategic validation and market readiness, as the company approaches its Series A funding round with plans for real-world deployment and commercialization. This indicates a significant step towards broader adoption and impact in early disease detection.

Company Intelligence Q&A

What is Nanose Medical's primary focus in diagnostics?

Nanose Medical focuses on developing non-invasive, AI-driven breath-sensing devices to detect unique biomarker fingerprints for early screening of diseases such as lung cancer and advanced liver fibrosis (MASH).

When was Nanose Medical founded and by whom?

Nanose Medical was founded in October 2019 by Orit Marom Albeck, Ilay Marom, Osnat Sella Tavor, and Prof. Hossam Haick.

Has Nanose Medical received any significant grants recently?

Yes, in May 2024, Nanose Medical received a grant of $3 million from the European Innovation Council. Additionally, in January 2024, the company received a grant from the Israel Innovation Authority.

What was a key finding presented at the EASL SLD Summit 2025?

At the EASL SLD Summit 2025, a poster was published detailing a novel point-of-care, rapid breath test developed by Nanose Medical to identify patients with metabolic dysfunction-associated steatotic liver disease with advanced fibrosis.

What is the reported accuracy of Nanose Medical's technology?

Nanose Medical's technology shows 80% accuracy in detecting unique biomarker fingerprints, based on thousands of samples and clinical data collected from 10 sites.